Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR-positive/HER2-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Testing effectiveness (Phase 2)Looking for participantsNCT06970912
What this trial is testing

CtDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHigh-risk Breast CancerEarly-Stage Breast Cancer+3 more
Peking University People's Hospital 393
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07336771
What this trial is testing

JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer (LABC)
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 60
Not applicableStudy completedNCT05155566
What this trial is testing

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

Who this might be right for
Breast Cancer Metastatic
Pfizer 847
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05431504
What this trial is testing

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Who this might be right for
Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 53
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06750848
What this trial is testing

Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jundong Wu 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07428018
What this trial is testing

Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib

Who this might be right for
Breast CancerHER2 + Breast CancerHR Positive+1 more
Mario Negri Institute for Pharmacological Research 150
Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Large-scale testing (Phase 3)UnknownNCT05253066
What this trial is testing

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Who this might be right for
Breast Neoplasms
Shengjing Hospital 130
Early research (Phase 1)Looking for participantsNCT07604571
What this trial is testing

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Who this might be right for
Advanced HR+/HER2- Breast Cancer
Novartis Pharmaceuticals 194
Large-scale testing (Phase 3)Active Not RecruitingNCT04055493
What this trial is testing

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Who this might be right for
Breast Cancer Female
Women's Cancer Study Group GmbH 1,684
Large-scale testing (Phase 3)Active Not RecruitingNCT03701334
What this trial is testing

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 5,101
Testing effectiveness (Phase 2)UnknownNCT06470672
What this trial is testing

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Fudan University 32
Testing effectiveness (Phase 2)UnknownNCT05800756
What this trial is testing

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

Who this might be right for
Breast Cancer
Yantai Yuhuangding Hospital 30
Testing effectiveness (Phase 2)Study completedNCT03222856
What this trial is testing

Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes

Who this might be right for
Breast Cancer
MedSIR 44
Large-scale testing (Phase 3)Active Not RecruitingNCT05365178
What this trial is testing

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Who this might be right for
HR-positive, HER2-negative Breast Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 432
Large-scale testing (Phase 3)Not Yet RecruitingNCT06996093
What this trial is testing

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
Fudan University 2,508
Testing effectiveness (Phase 2)UnknownNCT05775575
What this trial is testing

A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer

Who this might be right for
Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 65
Testing effectiveness (Phase 2)WithdrawnNCT02853071
What this trial is testing

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon
Next Page